{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:19:28Z","timestamp":1785424768567,"version":"3.56.0"},"reference-count":54,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["23K06689"],"award-info":[{"award-number":["23K06689"]}]},{"award":["23K06689"],"award-info":[{"award-number":["23K06689"]}],"id":[{"id":"https:\/\/ror.org\/048rj2z13","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Ovarian cancer stem cells (OvCSCs) are one of the main factors contributing to post-treatment recurrence and the poor prognosis of patients with ovarian cancer. Therefore, the development of therapeutic strategies targeting OvCSCs is needed to improve patient survival. We previously reported the high expression of survivin\/BIRC5 in OvCSCs and also that targeting pathways regulating survivin expression effectively suppressed OvCSC survival. In the present study, we tested a panel of agents consisting of FDA-approved drugs and compounds under clinical studies for their ability to suppress survivin expression in OvCSCs and identified clotrimazole (CTZ) as a potent candidate. The effects of CTZ on survivin expression were examined by RT-PCR and Western blot analyses. The effects of CTZ alone or in combination with anticancer agents on OvCSCs were evaluated using WST-8, PI uptake, and colony formation assays. CTZ preferentially impaired OvCSC survival by suppressing the c-myc\u2013survivin axis without affecting normal fibroblasts and enhanced the efficacy of platinum- and taxane-based chemotherapeutic agents. These results suggest that CTZ suppresses survivin expression in OvCSCs and enhances the effects of conventional ovarian cancer chemotherapeutic agents, supporting further investigations of this approach as a potential strategy for ovarian cancer treatment.<\/jats:p>","DOI":"10.3390\/ijms27146175","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:43:34Z","timestamp":1783683814000},"page":"6175","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clotrimazole Targets the c-Myc\u2013Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents"],"prefix":"10.3390","volume":"27","author":[{"given":"Yasufumi","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Department of Neurosurgery, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9904-8842","authenticated-orcid":false,"given":"Yurika","family":"Nakagawa-Saito","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-0146","authenticated-orcid":false,"given":"Shuhei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Department of Clinical Oncology, Yamagata Prefectural Shinjo Hospital, 720-1 Kanazawa, Shinjo 996-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Mitobe","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Department of Neurosurgery, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6850-8763","authenticated-orcid":false,"given":"Senri","family":"Takenouchi","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Togashi","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Department of Ophthalmology and Visual Sciences, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Sugai","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Seino","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ohta","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5212-1128","authenticated-orcid":false,"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chifumi","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"},{"name":"Institute for Promotion of Medical Science Research, Yamagata University Faculty of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-6076","authenticated-orcid":false,"given":"Masashi","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Molecular Cancer Science, Yamagata University School of Medicine, 2-2-2 Iida-nishi, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer: A Review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-026-01762-x","article-title":"Integrative Oncology for Biochemical Recurrence of Epithelial Ovarian Cancer","volume":"28","author":"Berman","year":"2026","journal-title":"Curr. Oncol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-025-02345-3","article-title":"A comprehensive overview of ovarian cancer stem cells: Correlation with high recurrence rate, underlying mechanisms, and therapeutic opportunities","volume":"24","author":"Alizadeh","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"189346","DOI":"10.1016\/j.bbcan.2025.189346","article-title":"Deciphering the \u201cRosetta Stone\u201d of ovarian cancer stem cells: Opportunities and challenges","volume":"1880","author":"Tan","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s12013-024-01385-8","article-title":"Advances in ovarian tumor stem cells and therapy","volume":"82","author":"Chen","year":"2024","journal-title":"Cell Biochem. Biophys."},{"key":"ref_6","first-page":"1327","article-title":"Survivin apoptosis: An interloper between cell death and cell proliferation in cancer","volume":"79","author":"Altieri","year":"1999","journal-title":"Lab. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","article-title":"Survivin: A new target for anti-cancer therapy","volume":"35","author":"Ryan","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/s13046-019-1362-1","article-title":"Cancer therapeutics using survivin BIRC5 as a target: What can we do after over two decades of study?","volume":"38","author":"Li","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.21873\/anticanres.12757","article-title":"A Small-molecule Kinase Inhibitor, CEP-1347, Inhibits Survivin Expression and Sensitizes Ovarian Cancer Stem Cells to Paclitaxel","volume":"38","author":"Togashi","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6699","DOI":"10.21873\/anticanres.13038","article-title":"AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel","volume":"38","author":"Yamamoto","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mendling, W., Atef El Shazly, M., and Zhang, L. (2020). Clotrimazole for Vulvovaginal Candidosis: More than 45 Years of Clinical Experience. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100274"},{"key":"ref_12","unstructured":"Khatter, N.J., and Khan, M.A.B. (2026). Clotrimazole. StatPearls, StatPearls Publishing."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/clinchem\/41.3.387","article-title":"HPLC measurement, blood distribution, and pharmacokinetics of oral clotrimazole, potentially useful antisickling agent","volume":"41","author":"Rifai","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1172\/JCI118537","article-title":"Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease","volume":"97","author":"Brugnara","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.jid.2021.05.017","article-title":"Xenobiotic Receptor CAR Is Highly Induced in Psoriasis and Promotes Keratinocyte Proliferation","volume":"141","author":"Lai","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3171\/jns.1999.90.5.0918","article-title":"Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro","volume":"90","author":"Khalid","year":"1999","journal-title":"J. Neurosurg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1677\/jme.1.02118","article-title":"Growth factor-dependent regulation of survivin by c-myc in human breast cancer","volume":"37","author":"Cosgrave","year":"2006","journal-title":"J. Mol. Endocrinol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Haque, R., Song, J., Haque, M., Lei, F., Sandhu, P., Ni, B., Zheng, S., Fang, D., Yang, J.M., and Song, J. (2017). c-Myc-Induced Survivin Is Essential for Promoting the Notch-Dependent T Cell Differentiation from Hematopoietic Stem Cells. Genes, 8.","DOI":"10.3390\/genes8030097"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Robinson, M., Gilbert, S.F., Waters, J.A., Lujano-Olazaba, O., Lara, J., Alexander, L.J., Green, S.E., Burkeen, G.A., Patrus, O., and Sarwar, Z. (2021). Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers, 13.","DOI":"10.3390\/cancers13020262"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"620523","DOI":"10.1155\/2011\/620523","article-title":"Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer","volume":"2011","author":"Steffensen","year":"2011","journal-title":"J. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cpt.2025.03.004","article-title":"Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy","volume":"4","author":"Karpe","year":"2026","journal-title":"Cancer Pathog. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15406","DOI":"10.1038\/s41598-024-66367-5","article-title":"Clotrimazole inhibits growth of multiple myeloma cells in vitro via G0\/G1 arrest and mitochondrial apoptosis","volume":"14","author":"Song","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/DDDT.S354205","article-title":"Clotrimazole Inhibits HCC Migration and Invasion by Modulating the ERK-p65 Signaling Pathway","volume":"16","author":"Liu","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"166263","DOI":"10.1016\/j.bbadis.2021.166263","article-title":"Clotrimazole presents anticancer properties against a mouse melanoma model acting as a PI3K inhibitor and inducing repolarization of tumor-associated macrophages","volume":"1867","author":"Ochioni","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Furtado, C.M., Marcondes, M.C., Sola-Penna, M., de Souza, M.L., and Zancan, P. (2012). Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030462"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/CAD.0b013e32833e8022","article-title":"Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro","volume":"21","author":"Liu","year":"2010","journal-title":"Anticancer Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13046-018-0835-y","article-title":"Emerging roles of Myc in stem cell biology and novel tumor therapies","volume":"37","author":"Yoshida","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-12-0977","article-title":"c-Myc and cancer metabolism","volume":"18","author":"Miller","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcdb.2015.08.003","article-title":"MYC and metabolism on the path to cancer","volume":"43","author":"Hsieh","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI116597","article-title":"Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives","volume":"92","author":"Brugnara","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zuccolini, P., Barbieri, R., Sbrana, F., Picco, C., Gavazzo, P., and Pusch, M. (2023). IK Channel-Independent Effects of Clotrimazole and Senicapoc on Cancer Cells Viability and Migration. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216285"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhou, L., Zheng, C., Ding, S., Wang, Z., Yang, Y., Wang, Y., He, G., Fu, S., and Deng, X. (2025). Lovastatin Targets the USP14-Survivin Axis to Suppress Triple-Negative Breast Cancer via Ubiquitin-Mediated Proteasomal Degradation. Cells, 14.","DOI":"10.3390\/cells14110816"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11033-025-10649-2","article-title":"Survivin knockout attenuates the progressiveness of BT549 triple negative-breast cancer cells: An in vitro study highlighting stemness and cellular stress response mechanisms","volume":"52","author":"Syahrani","year":"2025","journal-title":"Mol. Biol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbrc.2023.10.008","article-title":"BIRC5: A novel therapeutic target for lung cancer stem cells and glioma stem cells","volume":"682","author":"Kahm","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/cpr.12043","article-title":"KLF5 strengthens drug resistance of ovarian cancer stem-like cells by regulating survivin expression","volume":"46","author":"Dong","year":"2013","journal-title":"Cell Prolif."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","article-title":"Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines","volume":"9","author":"Lee","year":"2006","journal-title":"Cancer Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"17365","DOI":"10.1038\/s41598-019-53907-7","article-title":"FGF Signalling in the Self-Renewal of Colon Cancer Organoids","volume":"9","author":"Otte","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.febslet.2006.01.095","article-title":"Fibroblast growth factor signaling in embryonic and cancer stem cells","volume":"580","author":"Dvorak","year":"2006","journal-title":"FEBS Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.stem.2008.02.009","article-title":"Module map of stem cell genes guides creation of epithelial cancer stem cells","volume":"2","author":"Wong","year":"2008","journal-title":"Cell Stem Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"a014399","DOI":"10.1101\/cshperspect.a014399","article-title":"MYC cofactors: Molecular switches controlling diverse biological outcomes","volume":"4","author":"Hann","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12967-019-2005-1","article-title":"SNORD89 promotes stemness phenotype of ovarian cancer cells by regulating Notch1-c-Myc pathway","volume":"17","author":"Zhu","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.3802\/jgo.2020.31.e46","article-title":"SURF4 maintains stem-like properties via BIRC3 in ovarian cancer cells","volume":"31","author":"Yue","year":"2020","journal-title":"J. Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1535-7163.MCT-14-0801","article-title":"Targeting c-MYC in Platinum-Resistant Ovarian Cancer","volume":"14","author":"Mangala","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10549-022-06673-6","article-title":"MYC as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigations with the novel MYC inhibitor, MYCi975","volume":"195","author":"Tang","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Luffman, N., Ahmadinejad, F., Finnegan, R.M., Raymond, M., Gewirtz, D.A., and Harada, H. (2025). Effectiveness of PROTAC BET Degraders in Combating Cisplatin Resistance in Head and Neck Cancer Cells. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26136185"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(25)09525-4","article-title":"Oral administration of clotrimazole and blockade of human erythrocyte Ca(++)-activated K+ channel: The imidazole ring is not required for inhibitory activity","volume":"273","author":"Brugnara","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02977701","article-title":"Enhanced bioavailability of poorly water-soluble clotrimazole by inclusion with beta-cyclodextrin","volume":"30","author":"Prabagar","year":"2007","journal-title":"Arch. Pharm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"94872","DOI":"10.18632\/oncotarget.22033","article-title":"Repositioning CEP-1347, a chemical agent originally developed for the treatment of Parkinson\u2019s disease, as an anti-cancer stem cell drug","volume":"8","author":"Okada","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","first-page":"4723","article-title":"Requirement of JNK signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells","volume":"34","author":"Seino","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"27021","DOI":"10.18632\/oncotarget.8395","article-title":"The novel JNK inhibitor AS602801 inhibits cancer stem cells in vitro and in vivo","volume":"7","author":"Okada","year":"2016","journal-title":"Oncotarget"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1111\/febs.15187","article-title":"Verteporfin inhibits oxidative phosphorylation and induces cell death specifically in glioma stem cells","volume":"287","author":"Kuramoto","year":"2020","journal-title":"FEBS J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Nakagawa-Saito, Y., Mitobe, Y., Suzuki, S., Togashi, K., Sugai, A., Kitanaka, C., and Okada, M. (2023). Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310817"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nakagawa-Saito, Y., Mitobe, Y., Togashi, K., Suzuki, S., Sugai, A., Takenouchi, S., Nakamura, K., Sonoda, Y., Kitanaka, C., and Okada, M. (2024). The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25073948"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"90996","DOI":"10.18632\/oncotarget.18827","article-title":"Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo","volume":"8","author":"Takeda","year":"2017","journal-title":"Oncotarget"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6175\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:47:56Z","timestamp":1783684076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/14\/6175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":54,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ijms27146175"],"URL":"https:\/\/doi.org\/10.3390\/ijms27146175","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}